United States · Venture startup
Funding summaryUpdated 26 Oct 2026
$41Mraised across 2 rounds since 2021, from 2 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Source recordedSEC filing: $24M sold, first sale Jun 2023
Hatteras Venture PartnersLead
TEDCO
Alexandria Real Estate Equities
Genesys Capital
Sanofi Ventures
T1D Fund
Point Field PartnersReported by Hatteras Venture PartnersSEC filing: $14M sold, first sale Jun 2021
From the SEC filings it signed: 1 on the team.
On the board, as filediAlex MartinBenjamin ScruggsJamie StiffKatie ElliasMegan Krench
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Missing a round, or an investor who was in one? Tell us.
Veralox Therapeutics's investors include Hatteras Venture Partners, TEDCO, Alumni Ventures, Alexandria Venture Investments and Alexandria Real Estate Equities, and 7 more on record.
Veralox Therapeutics has raised $41M across 2 rounds since 2021.
Veralox Therapeutics's most recent round was a Venture of $24M in Jun 2023.
Its most recent round, $24M in Jun 2023, is also its largest on record.
Veralox Therapeutics's first round on record, in Jun 2021, was backed by Hatteras Venture Partners, TEDCO and Alexandria Real Estate Equities and 6 others.
Veralox Therapeutics's latest named round is a Venture, in Jun 2023.
Veralox Therapeutics is based in the United States.
Hatteras Venture Partners led the Series A in 2021.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
